BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company has sold a MicroThermX® Microwave Ablation System (MicroThermX®) to the University of Miami Hospital and Clinics (UMHC) to include the Sylvester Comprehensive Cancer Center (Sylvester) and the University of Miami Hospital. The MicroThermX® will be used in both centers.
Sylvester/UMHC serves as the hub for cancer diagnosis and treatment throughout the South Florida area. The UMHC comprehensive network includes three hospitals, more than 30 outpatient facilities, and more than 1,500 physicians and scientists. Sylvester treats more than 4,100 new cancer patients each year, and has transformed cancer research and treatment in South Florida.
"We are excited to have state-of-the-art ablation treatment with the MicroThermX® available in these prestigious cancer care facilities," stated Sam Maravich, BSD's Vice President of Sales and Marketing. “UMHC purchased the MicroThermX® following extensive clinical evaluations. Sylvester previously offered only radiofrequency (RF) ablation, but decided to acquire the MicroThermX® because of its technological advantages. Published studies have demonstrated that microwave ablation has multiple advantages over RF ablation, and the innovative design of the MicroThermX® provides physicians the ability to precisely target the ablation zone to numerous sizes and shapes of tumors."
About the MicroThermX® Microwave Ablation System
The MicroThermX® is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide a wide range of uniform zones of ablation. The MicroThermX® introduces into the Company’s product line innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX® System, which allows BSD to market the MicroThermX® in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX® to a number of international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia), while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.